Elicio Therapeutics, Inc. (ELTX)
(Delayed Data from NSDQ)
$8.65 USD
-0.55 (-5.98%)
Updated Aug 11, 2025 04:00 PM ET
After-Market: $9.45 +0.80 (9.25%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth B Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Elicio Therapeutics, Inc.'s return on equity, or ROE, is -555.45% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.66%. While this shows that ELTX has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
ELTX 8.65 -0.55(-5.98%)
Will ELTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ELTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ELTX
Here's Why Elicio Therapeutics (ELTX) Could be Great Choice for a Bottom Fisher
Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year?
ELTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Elicio Therapeutics (ELTX) Upgraded to Buy: Here's What You Should Know
All You Need to Know About Elicio Therapeutics (ELTX) Rating Upgrade to Strong Buy
Other News for ELTX
Elicio Therapeutics GAAP EPS of -$0.66
JonesTrading Sticks to Their Buy Rating for Elicio Therapeutics (ELTX)
Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate ...
Elicio Therapeutics (ELTX) Advances with Positive Interim Trial Review
Elicio announces positive recommendation by IDMC to continue ELI-002 Phase 2